Both Pfizer and BioNTech announced that their mRNA-based vaccine had been shown to be effective at blocking the virus in 90 percent of participants in stage 3 of its clinical trial, which included 43,358 participants. The vaccine uses a two-dose process, and Pfizer says, “no serious safety concerns have been...
https://www.techspot.com/news/87521-news-covid-19-vaccine-90-effectiveness-sees-pandemic.html?utm_source=dlvr.it&utm_medium=blogger
https://www.techspot.com/news/87521-news-covid-19-vaccine-90-effectiveness-sees-pandemic.html?utm_source=dlvr.it&utm_medium=blogger